Shots:
The P-III study evaluates VV116 (JT001) vs Paxlovid in 822 patients with COVID-19 who are at high risk for progression to sev. COVID-19 including death
The trial met its pre-specified 1EPs & 2EPs i.e., the therapy exhibited a shorter time to sustained clinical recovery and was statistically superior, no COVID-19 disease progression or death were observed along with time to sustained disappearance of clinical symptoms & the time to patient testing negative for SARS-CoV-2 & has a good safety profile, the overall incidence of AE was lower than Paxlovid
In the P-I trials, VV116 exhibited good safety, tolerability & PK in healthy patients. VV116 is an oral nucleoside analogue therapy that can stop SARS-CoV-2 from replicating
